Monitoring of omalizumab therapy in children and adolescents

Background: Omalizumab is a successfully implemented supplementary therapy for improving asthma control in children aged 6 years and older with severe persistent allergic asthma. The dosage of omalizumab depends on body weight and IgE level, yet no parameter has been established to guide dosage chan...

Descripción completa

Detalles Bibliográficos
Autores principales: Steiß, J.O., Schmidt, A., Lindemann, H., Rudloff, S., Staatz, A., Strohner, P., Becher, G. , Nährlich, L., Zimmer, K.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881852/
https://www.ncbi.nlm.nih.gov/pubmed/31826035
http://dx.doi.org/10.5414/ALX01337E

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881852/
https://www.ncbi.nlm.nih.gov/pubmed/31826035
http://dx.doi.org/10.5414/ALX01337E

Ejemplares similares